SJP 0118

Drug Profile

SJP 0118

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Senju Pharmaceutical
  • Developer Senju Pharmaceutical; Tottori University Hospital
  • Class Antibacterials; Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Blepharitis; Infectious conjunctivitis; Ocular inflammation

Most Recent Events

  • 13 Mar 2018 Senju Pharmaceutical completes a phase III trial for Infectious conjunctivitis in Japan (UMIN000026494)
  • 15 May 2017 Senju Pharmaceutical initiates enrolment in a phase III trial for Infectious conjunctivitis (In adolescents, In children, In adults) in Japan (Instillation) (UMIN000027039)
  • 02 May 2017 Senju Pharmaceutical plans a phase III trial for Infectious conjunctivitis (In adolescents; In children; In adults) in Japan (UMIN000027039)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top